Total Temporomandibular Joint Replacement System
BIOMET MICROFIXATION, INC · Decision date Feb 19, 2026
What did the FDA decide?
FDA records P020016/S013 as a supplement to PMA P020016, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 19, 2026.
FDA approval order statement
to include a surface roughness inspection method for the Total Temporomandibular Joint Replacement system (TMJ)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Dental
- Decision date
- Feb 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P020016/S013
- Regulatory pathway
- PMA supplement
- Applicant
- BIOMET MICROFIXATION, INC
- Product code
- LZD
- Decision code
- OK30
- Decision date
- Feb 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Joint, temporomandibular, implant.
- Applicant
- BIOMET MICROFIXATION, INC
- Product code
- LZD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P020016/S013 received
Application receipt date recorded by FDA.
P020016/S013 · FDA decision
30-Day Notice
P020016/S010 · Related supplement
Total Temporomandibular Joint Replacement System
Timeline entries are records held by MedtechLedger for P020016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P020016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Total Temporomandibular Joint Replacement SystemP020016/S010 | BIOMET MICROFIXATION, INC | PMA supplement | Jul 27, 2026 | FDA |
Explore the linked device profile
Other records with product code LZD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Stryker Leibinger GmbH & Co. KG | PMA supplement | Mar 6, 2026 | FDA | |
| Stryker Leibinger GmbH & Co. KG | PMA supplement | Jul 23, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BIOMET MICROFIXATION, INC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1520 Tradeport Dr., Jacksonville, FL, 32218
Sources and methodology
- Original FDA record: P020016/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

